CTNI-70. LONG-TERM SURVIVAL IN GLIOBLASTOMA PATIENTS AFTER TUMOR TREATING FIELDS (TTFIELDS) THERAPY

PURPOSE: Glioblastoma multiforme (GBM) is the most common and malignant primary intracranial tumor and traditionally has a median survival of only 10 to 14 months, with only 3 to 5% of patients surviving more than three years. Recurrence (RGBM) is nearly universal, and further decreases the median s...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Neuro Oncol
Hoofdauteurs: Rulseh, Aaron, Derner, Adam, Sroubek, Jan, Klener, Jan, Vymazal, Josef
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2020
Onderwerpen:
Clinical Trials: Non-Immunologic
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651202/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.236
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items